THE herpes simplex virus type 1 is best known as the villain behind the dreaded cold sore. When it’s not triggering eruptions ...

(NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies and assets, including best-in-class Bruton’s tyrosine ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company’s President ...

AiCuris Anti-infective Cures AG today announced the initiation of its Phase 1, first-in-human trial of AIC468, a novel antisense oligonucleotide. AIC468 is an antiviral agent which aims to treat BK ...

Look in your cabinets for some potential cold sore relief—and possibly ways to prevent future breakouts, too The post 12 Cold ...

The breakthrough treatment uses cutting-edge DNA sequencing that may help millions of people ... A new therapeutic virus, RP1, has been created from the herpes simplex virus, which causes cold sores.

Herpesviruses are common co-pathogens in individuals infected with human immunodeficiency virus (HIV). Herpes simplex virus ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

According to a new market research report, 'IVD Assay Development Market Size, Share, Forecast, & Trends Analysis by Offering ...

Long-term, low-dose antiviral treatment opens doors for treating shingles in the eye. Will antiviral drug valacyclovir ...

The global Oncolytic Virus Cancer Therapy (OVT) market is expected to be valued at USD 22.86 million in 2023, with ...

NanoViricides, Inc. (NYSE Amer.: NNVC ) (the “Company”), a clinical stage global leader in broad-spectrum antiviral ...